Extended Half‐Life Recombinant Factor VIII Conjugated With Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples
Haemophilia · 2026-11 · 32 (6) · 1522-1531
DOI: 10.1111/hae.70361 ↗Abstract
ABSTRACT Introduction Various extended half‐life recombinant factor VIII (EHL‐FVIII) products have been designed to improve the pharmacokinetic properties of FVIII, allowing prolonged haemostatic coverage and reducing the injection burden in people with haemophilia A. Nevertheless, the influence of direct molecular attachment on fibrin clot formation and stability remains to be investigated. Aim To investigate the stability and architecture of fibrin clots in the presence of various types of EHL‐FVIII. Methods Three EHL‐FVIII products with direct attachment modifications (damoctocog alfa pegol, efraloctocog alfa, and rurioctocog alfa pegol) and two standard FVIII (turoctocog alfa and rurioctocog alfa) were added to FVIII‐deficient whole blood and plasma at various concentrations for functional comparison. Under whole‐blood conditions, functional assays were performed using rotational thromboelastometry (ROTEM) and a microchip flow‐chamber system (T‐TAS). Under plasma‐based conditions, fibrin fibres were directly observed by electron microscopy and coagulation function was assessed using clot waveform analysis (CWA). Anticoagulant and fibrinolytic activities were evaluated by CWA with the addition of activated protein C and tissue plasminogen activator, respectively. Results At equivalent activity levels, none of the assays revealed significant differences among the three EHL products or the two standard products. All contributed comparably to fibrin clot formation and stability, as well as to anticoagulation and fibrinolysis functions. Conclusion Direct modification by PEGylation or IgG‐Fc fusion to impart EHL characteristics preserves the functional properties of native FVIII.
EUVIMED